More than 120 senior executives from nearly 100 pharmaceutical companies have resigned, including a large number of deputy general managers and core technicians

In the market environment such as medical reform and centralized procurement, the frequent flow of executives in the pharmaceutical industry has become a topic of high concern in the industry
.
According to the author's incomplete statistics, in just over three months since 2022, more than 120 executives from nearly 100 pharmaceutical companies in China have left, and there are many chairmen, general managers, deputy general managers, presidents, and deputy general managers.
President, core technical personnel and other positions
.
It is understood that core technicians are generally responsible for the research and development projects of pharmaceutical companies, mastering patented technologies, etc.
, which are related to the core competitiveness of enterprises
.
Therefore, the departure of core technical personnel may have an impact on the competitiveness of enterprises
.
Since the beginning of this year, many core technicians of listed pharmaceutical companies have resigned
.
For example, on the evening of March 7, Dory Pharmaceuticals announced that Yao Hongjun, the company's deputy general manager, and Van der Hua, one of the other core personnel, resigned, and Jane Huang (Huang Weijuan), a core technician of BeiGene, was also considering applying for resignation in the near future due to personal career planning;2 In this month, Zhang Hewen, the core technician of Haooubo, resigned, Xu Zheng, the core technician of Kain Technology, and Ding Jiansheng, the core technician of Nuotai Biotechnology, also announced their resignation; Technical staff Li Huiliang and others announced their resignation
.
In addition to core technical personnel, general managers, deputy general managers, presidents, and vice presidents are also the objects of concern in pharmaceutical companies
.
Affected by changes in the industry environment, a large number of executives have resigned this year
.
For example, in mid-February news, Buchang Pharmaceutical announced that the company received a written resignation report submitted by director and vice president Li Weijun
.
According to the report, Li Weijun applied to resign as the company's director, vice president and member of the compensation and appraisal committee of the board of directors due to personal reasons, and at the same time resigned from all positions held in the company's subsidiaries
.
On February 22, Jinhua Co.
, Ltd.
announced that due to work needs, Zhang Chaoyang, chairman of the company, applied to resign from his position as chairman of the company, and continued to serve as a director of the company after his resignation.

.
On February 12, Harbin Pharmaceutical Co.
, Ltd.
issued an announcement that due to retirement, Mr.
Zhang Zhenping resigned from the company's vice chairman, director, and member of the Remuneration and Assessment Committee.
After resigning, he will not hold any other positions in the company.
The resignation report submitted by him will be delivered to the board of directors.
effective date
.
On February 8, Zhengye Bio announced that Ms.
Shao Yu voluntarily resigned from the company's director and chairman positions due to personal reasons, and will no longer hold other positions in the company after her resignation
.
On January 28, China Resources Pharma issued an announcement on changes in the chairman, general manager and directors, stating that Han Yuewei would no longer serve as its director, chairman and legal representative, and Zhao Bingxiang would no longer serve as a director
.
On January 13, Liu Wenjing, chairman and president of Bluesail Medical, said that due to the consideration of the company's long-term strategic inheritance, incremental business development and the age-level construction of the company's management team, he will no longer serve as the president
.
On January 10, Dong’e Ejiao announced that Han Yuewei had applied to resign as chairman and director of the tenth session of the board of directors due to job changes, and also resigned as chairman of the strategy committee of the tenth session of the board of directors
.
On the same day, Gao Dengfeng, the president and legal representative of Dong'e Ejiao, applied for resignation from the above two positions due to changes in job content
.
On January 3, Huahai Pharmaceutical announced that the board of directors recently received the resignation document of Wang Jie, the vice president of the company.
Since receiving the resignation document, Wang Jie will no longer hold any positions in the company
.
In addition, since the beginning of this year, Wang Ruwei, deputy general manager of Tigermed, Gui Yaokui, deputy general manager of Shengxiang Bio, Zhu Lin, deputy general manager of Sinopharm, Xue Yuwei, deputy general manager of Jiuqiang Bio, and Zhang Wanheng, deputy general manager of Zixin Pharmaceutical, etc.
resign
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.